We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

News

News

Human Genome Sciences Awarded Two-Phase Contract to Supply ABthrax™

Human Genome Sciences will supply ten grams of ABthrax within two months for use in comparative testing to be conducted by HHS.
News

NIH Renews Its Pharmacogenetics Research Network

The NIH anticipates spending $150 million over five years to renew its Pharmacogenetics Research Network.
News

Celliance Acquires Gene Expression Technology

The UCOE technology will augment Celliance’s cell line development and protein expansion capabilities.
News

Chemicon and Axordia to Co-Develop Antibody Markers

Axordia will contribute proprietary expertise and materials for antibody generation and antibody characterization.
News

Illumina to Develop Genotyping BeadChip

Illumina to collaborate with the WTSI and WT-CCC on the design of a custom Sentrix® BeadChip.
News

Collaborations to Develop Applications Using HyperSense DNP Technology for NMR

Researchers will use HyperSense™ to identify biological markers for cancer, to develop methods for determining the kinetics and dynamics of protein-ligand interactions and for rapid characterization of compound libraries.
News

Case Western Reserve University Received $5 Million Grant

The grant will support the establishment of the Case Proteomics Center.
News

Marine Toxins Show Promise as Cancer Drugs

Researchers have determined how this class of toxins interacts with actin, a protein that provides an excellent target for drugs that could inhibit rapid growth of cancer cell.
News

Compound Reveals Link Between Signaling Protein And Cell Migration

The protein, known as RKIP, controls activity of kinases, a type of enzyme that acts as a key component in the biochemical signaling pathways responsible for determining almost all cellular activity.
News

Chiral Quest Subsidiary Signs License Agreement with

This agreement provides Merck with access to a broad range of proprietary ligands and catalysts.
Advertisement